» Articles » PMID: 36017534

Maximizing MRNA Vaccine Production with Bayesian Optimization

Overview
Publisher Wiley
Specialty Biochemistry
Date 2022 Aug 26
PMID 36017534
Authors
Affiliations
Soon will be listed here.
Abstract

Messenger RNA (mRNA) vaccines are a new alternative to conventional vaccines with a prominent role in infectious disease control. These vaccines are produced in in vitro transcription (IVT) reactions, catalyzed by RNA polymerase in cascade reactions. To ensure an efficient and cost-effective manufacturing process, essential for a large-scale production and effective vaccine supply chain, the IVT reaction needs to be optimized. IVT is a complex reaction that contains a large number of variables that can affect its outcome. Traditional optimization methods rely on classic Design of Experiments methods, which are time-consuming and can present human bias or based on simplified assumptions. In this contribution, we propose the use of Machine Learning approaches to perform a data-driven optimization of an mRNA IVT reaction. A Bayesian optimization method and model interpretability techniques were used to automate experiment design, providing a feedback loop. IVT reaction conditions were found under 60 optimization runs that produced 12 g · L in solely 2 h. The results obtained outperform published industry standards and data reported in literature in terms of both achievable reaction yield and reduction of production time. Furthermore, this shows the potential of Bayesian optimization as a cost-effective optimization tool within (bio)chemical applications.

Citing Articles

Bacteriophage RNA polymerases: catalysts for mRNA vaccines and therapeutics.

Nair A, Kis Z Front Mol Biosci. 2024; 11:1504876.

PMID: 39640848 PMC: 11617373. DOI: 10.3389/fmolb.2024.1504876.


Transfer learning Bayesian optimization for competitor DNA molecule design for use in diagnostic assays.

Sedgwick R, Goertz J, Stevens M, Misener R, van der Wilk M Biotechnol Bioeng. 2024; 122(1):189-210.

PMID: 39412958 PMC: 11632174. DOI: 10.1002/bit.28854.


A (RP)UHPLC/UV analytical method to quantify dsRNA during the mRNA vaccine manufacturing process.

Rosa S, Zhang S, Sari Y, Marques M Anal Methods. 2024; 16(30):5146-5153.

PMID: 39011770 PMC: 11293613. DOI: 10.1039/d4ay00560k.


Quality by Digital Design for Developing Platform RNA Vaccine and Therapeutic Manufacturing Processes.

Nair A, Loveday K, Kenyon C, Qu J, Kis Z Methods Mol Biol. 2024; 2786:339-364.

PMID: 38814403 DOI: 10.1007/978-1-0716-3770-8_16.


Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production.

Sari Y, Rosa S, Jeffries J, Marques M Sci Rep. 2024; 14(1):9655.

PMID: 38671016 PMC: 11053036. DOI: 10.1038/s41598-024-59978-5.


References
1.
Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

2.
Hayman B, Suri R, Prasad S . COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective. Vaccine. 2021; 39(35):4932-4937. PMC: 8275514. DOI: 10.1016/j.vaccine.2021.07.007. View

3.
Wu M, Asahara H, Tzertzinis G, Roy B . Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. RNA. 2020; 26(3):345-360. PMC: 7025508. DOI: 10.1261/rna.073858.119. View

4.
Borkotoky S, Meena C, Bhalerao G, Murali A . An in-silico glimpse into the pH dependent structural changes of T7 RNA polymerase: a protein with simplicity. Sci Rep. 2017; 7(1):6290. PMC: 5524818. DOI: 10.1038/s41598-017-06586-1. View

5.
Rosa S, Prazeres D, Azevedo A, Marques M . mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021; 39(16):2190-2200. PMC: 7987532. DOI: 10.1016/j.vaccine.2021.03.038. View